Monte Rosa Therapeutics
NASDAQ: GLUEBoston, US · Founded 2019 · Delaware corporation · 8 known investors
Monte Rosa develops molecular glue degrader (MGD) therapeutics using MGD chemistry, artificial intelligence, structural biology, and proteomics to target previously undruggable or inadequately drugged disease targets. The company operates in drug discovery and pharmaceutical development.
AI & Machine LearningBiotechDeep TechHealthtech
Founders & leadership
MW
ST
Sharon TownsonPh.D., Chief Scientific Officer
JC
John CastlePh.D., Chief Data and Information Officer
FJ
Filip JankuM.D., Ph.D., Chief Medical Officer
PN
Phil NicksonPh.D., J.D., Chief Business and Legal Officer
MW
Magnus WalterDPhil, Chief Technology Officer
JC
Jennifer ChampouxChief Operating Officer
AF
Andrew FunderburkChief Investor Relations and Strategy Officer
Board
AM
BB
AB
KB
Kim BlackwellBoard director
Investors · 8
Aisling Capital✓ verifiedNew York
New Enterprise Associates (NEA)✓ verifiedMenlo Park · $200K – $40Mvia Ali Behbahani · board
Versant Ventures✓ verifiedSan Francisco · $250K – $5M
HBM Partners✓ verifiedZug · $5M – $50M
Amzak HealthNew York
Avoro Capital AdvisorsNew York
GV (Google Ventures)Mountain View · $250K – $50M
Dimension CapitalreportedSan Francisco · $1M – $10M
Reported raises · per SEC filings
Form D private placements$143M disclosed across 2 rounds · 2020–2021
▶$95MraisedMar 2021 · 23 investors · BiotechnologyRule 506(b)
▶$95MraisedMar 2021 · 23 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Markus WarmuthExecutive Officer, Director
- Alexander MaywegDirector
- Bradley BolzonDirector
- Ali BehbahaniDirector
- Kim BlackwellDirector
- Drew SchiffDirector
- Chandra P. LeoDirector
- Christine SiuDirector
- Ajim TamboliExecutive Officer
- Offering amount
- $95M
- Amount sold
- $95M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$48MraisedSep 2020 · 17 investors · BiotechnologyRule 506(b)
▶$48MraisedSep 2020 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alexander MaywegDirector
- Bradley BolzonDirector
- Markus WarmuthExecutive Officer, Director
- Ali BehbahaniDirector
- Kim BlackwellDirector
- Offering amount
- $96M
- Amount sold
- $48M
- First sale
- Sep 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapBioworld27 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Seeking Alpha19 shared keywordsSeeking Alpha is a financial research platform that provides stock analysis, investment tools, and market coverage across asset classes to investors. The platform aggregates research from thousands of analysts and investors, offering ratings, articles, and investment ideas.
Companies competing with Monte Rosa Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Monte Rosa Therapeutics do?
- Monte Rosa develops molecular glue degrader (MGD) therapeutics using MGD chemistry, artificial intelligence, structural biology, and proteomics to target previously undruggable or inadequately drugged disease targets. The company operates in drug discovery and pharmaceutical development.
- Who are Monte Rosa Therapeutics's investors?
- Monte Rosa Therapeutics's investors include Aisling Capital, New Enterprise Associates (NEA), Versant Ventures, HBM Partners, Amzak Health, Avoro Capital Advisors, GV (Google Ventures), Dimension Capital.
- How much funding has Monte Rosa Therapeutics raised?
- Monte Rosa Therapeutics has disclosed $143M raised across 2 rounds.
- Where is Monte Rosa Therapeutics headquartered?
- Monte Rosa Therapeutics is headquartered in Boston, US.